| Name | Title | Contact Details |
|---|
Focalyst is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Delfi Medical Innovations is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DOTMED.COM Inc. is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dialyze Direct provides staff assisted home hemodialysis services to elderly patients with End Stage Renal Disease who reside in Nursing Homes. Our mission is to deliver innovative and compassionate dialysis care to geriatric patients in Skilled Nursing Facilities, enhancing their quality of life while significantly reducing overall costs by improving outcomes, eliminating transportation and minimizing re-hospitalizations. The Dialyze Direct program permits an unprecedented degree of on-site coordination of care and sharing information with the nursing home staff, with respect to ESRD care, that include nursing, dietary and social work collaboration. Dialyze Direct has re-purposed home dialysis technology, with enhanced and proprietary protocols that are better suited to the special needs of geriatric patients with multiple co-morbid conditions resulting in improved outcomes, shortened recovery times, increased rehab score gains and decreased re-hospitalizations.
CeQur is dedicated to helping people with type 2 diabetes manage their disease by developing and commercializing simple drug delivery devices that can be easily integrated into daily life. The company`s lead product, PaQ, is a wearable insulin delivery device that delivers both basal and bolus insulin for 3 days at a time. Its simple, discreet design enables people to easily experience the benefits of intensive insulin therapy, while remaining free from the burdens of daily insulin injections. CeQur SA was established in January 2008 as a spinout from Danfoss A/S, a global Danish industrial products group that developed the initial concept of the CeQur technology. CeQur recently completed a clinical study evaluating PaQ among people with type 2 diabetes with positive results. The company has advanced the technology to a commercial product obtaining a CE mark for PaQ in 2012. CeQur is headquartered in Horw, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts.